Skip to main content
AARD logo

AARD · Aardvark Therapeutics, Inc.

Track AARD — free
$6.62 -0.19 (-2.79%) At close · Aug 27
Market Cap
$149.04M
Shares
21.88M

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue
$0
FY2025
Net Income
-$57.59M -179.7%
FY2025 Net Income FY2024–FY2025
Diluted EPS
-$2.93 +43.1%
FY2025 Diluted EPS FY2024–FY2025
Operating Cash Flow
-$54.17M -199.5%
FY2025 Operating Cash Flow FY2024–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024
$0
$4.06M $5.14M $2.41M
$55.06M $48.94M $17.36M
$18.9M $13.79M $5.31M
$36K $16K
$73.96M $62.73M $22.79M
-$73.96M -$62.73M -$22.79M
-$62.69M -$22.77M
$4.07M $5.13M $2.2M
$0 $0
-$69.89M -$57.59M -$20.59M
-$69.89M -$57.51M -$20.59M
USD/shares -$3.21 -$2.93 -$5.15
USD/shares -$3.21 -$2.93 -$5.15
shares 19.62M 4M
shares 19.62M 4M
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
Peer median 4.73×
EV/EBIT
Peer median 12.45×
P/E (TTM)
Peer median 10.33×

Peer medians compare against the 303 similar-size Biotechnology companies (of 534 listed).

Key facts CIK 1774857 CUSIP 002942100 13F (30d) 59 filings 59 filers Visit website Investor relations